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Getting Rid of Rotavirus
On 12 December 1997, the FDA's Vaccine
and Related Biologicals Products Advisory
Committee unanimously concluded that
RotaShield, the first vaccine for rotavirus-
a highly contagious disease that causes life-
threatening diarrhea in young children-is
safe and effective, and recommended
licensing.
In the United States alone, rotavirus
causes 3 million cases ofchildhood diarrhea,
resulting in 500,000 doctor visits, 100,000
hospitalizations, and up to 100 deaths annu-
ally. Direct costs of the disease run to as
much as $400 million and indirect costs
(such as lostwork time for parents) total $1.4
billion. Worldwide, rotavirus kills 873,000
children each year, largely in underdeveloped
countries. The vaccine is intended to be
administered in three doses at 2, 4, and 6
months of age when children receive their
polio vaccine.
The RotaShield vaccine was created and
patented by virologist and physician Albert
Kapikian and his colleagues at the National
Institute ofAllergy and Infectious Diseases in
Bethesda, Maryland. Kapikian, head of the
epidemiology section of the Laboratory of
Infectious Diseases, has devoted nearly 25
years to studying rotavirus. "It's exciting and
gratifying as a physician to see that most
babies can be protected from severe diarrhea
with a product developed in our laboratory,"
he says.
Australian virologists discovered rotavirus
in 1973. Later, several epidemiological stud-
ies proved that rotavirus was the most impor-
tant agent involved in infantile diarrhea
worldwide. Kapikian's ingenuity and perse-
verance helped overcome obstacles in creat-
ing the vaccine. For instance, human
rotavirus resisted growth in cell cultures,
whereas simian rotavirus grew well. The
researchers worked to determine whether an
animal rotavirus could protect humans,
much in the same way that Edward Jenner
determined 200 years ago that vaccinating
people with cowpox could prevent smallpox.
The final vaccine contains a weakened form
of rotavirus obtained from rhesus monkeys,
bioengineered with three genes from human
rotavirus. This combination proved most
effective at protecting people against the four
most prevalent clinical strains ofrotavirus.
The vaccine was tested successfully in
numerous clinical trials. Among 2,000
infants in Venezuela, the vaccine reduced
severe diarrheal illness by 88% and dehydra-
tion by 75%, and decreased hospitalizations
Last of a dying breed? A new vaccine expected to be approved by the FDA may mean the end of
rotavirus outbreaks.
by 70%. This study, reported in the 23
October 1997 issue of the New England
JournalofMedicine, was the largest and most
successful trial ofthe vaccine in a developing
country. A multi-center trial conducted in
the United States of 1,200 children showed
that the vaccine protected 80% of the chil-
dren against severe diarrhea and 100%
against dehydration, as described in the
January 1996 issue of Pediatrics. Another
study, which appeared in the 25 October
1997 issue of Lancet, concluded that when
tested on 2,400 Finnish children the vaccine
reduced severe diarrhea by 91%, clinic visits
for dehydration by 97%, and hospitalizations
by 100%. In the latest study, published in
the October 1997 issue of the Journal of
Pediatrics, the vaccine prevented 69% of
severe cases ofdiarrhea on American Indian
reservations, where incidence rates of
rotavirus disease run higher than for the gen-
eral population. "The routine use ofthis vac-
cine could save lives and prevent illness," says
Mathuram Santosham, director ofthe Johns
Hopkins Center for American Indian and
Alaskan Native Health in Baltimore,
Maryland. In all clinical tests, the vaccinewas
safe andwell-tolerated.
About 90% of all children are infected
by rotavirus by age three regardless of
hygienic conditions. Diarrhea is considered a
normal part of childhood, and few hear
about the small number ofchildren who die
yearly from rotavirus. Although a current
television advertisement for a bathroom
cleaner mentions that it kills rotavirus, in
reality "parents in the U.S. don't know that
rotavirus is a problem," says senior clinical
scientist Michael Pastorino ofWyeth-Ayerst
Research in Radnor, Pennsylvania, a division
of the company seeking licensure for the
RotaShield vaccine. Both parents and physi-
cians need to be educated about the new
vaccine.
Wyeth-Ayerst is seeking a universal rec-
ommendation that all children be vaccinated
for rotavirus from the Advisory Committee
for Immunization Practices at the CDC,
which sets the schedule ofchildhood immu-
nizations.
Stockpiling Safety?
By spring, the Nuclear Regulatory
Commission (NRC) is expected to act, once
again, on the 15-year-old issue ofwhether it
makes sense for states to consider stockpiling
thousands oftablets ofpotassium iodide (KI)
near nuclear power plants in case ofan emer-
gency. No one disputes that KI, a benign
substance longapproved for over-the-counter
use, is an effective thyroid-blocking agent.
And no one is arguing that the cost ofKI is
prohibitive. A 130-mg tablet costs $.07; sup-
plying all residents within five miles ofone of
the United States' 107 operating nuclear
reactors would cost as little as $200,000
(although distributing and disposing of the
supply would add costs). Few even question
the safety ofthe tablets. The issue is whether
having KI on hand would make some resi-
dents trust their fate to a pill rather than to
evacuation.
Many states, as well as the nudear indus-
try, believe evacuation should be the first line
of protective action in a nuclear emergency.
A 128 Volume 106, Number 3, March 1998 * Environmental Health Perspectives